SUBSCRIBE
SUBSCRIBE

Schizophrenia

Pictured: Facade of the U.S. Patent and Trademark
Drug Development
Otsuka’s Longer-Acting Schizophrenia Injection to Offset Abilify Patent Loss
A longer-acting formulation of Otsuka Pharmaceuticals’ aripiprazole could help soften the blow of Abilify Maintena’s loss of exclusivity coming later this year, according to a new report from GlobalData.
February 15, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
PRESS RELEASES
Press Releases
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
August 20, 2025
 · 
11 min read
Press Releases
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
August 18, 2025
 · 
12 min read
Press Releases
BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates
August 13, 2025
 · 
16 min read
Press Releases
Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)
August 12, 2025
 · 
9 min read
Press Releases
Newron Notes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction
August 12, 2025
 · 
10 min read
Press Releases
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
August 12, 2025
 · 
14 min read
Press Releases
Boehringer and Click Therapeutics’ investigational prescription digital therapeutic CT-155 meets primary endpoint in CONVOKE study for negative symptoms in schizophrenia
August 8, 2025
 · 
9 min read
Press Releases
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
August 6, 2025
 · 
12 min read
Press Releases
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
August 4, 2025
 · 
9 min read
Press Releases
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
July 31, 2025
 · 
20 min read
Press Releases
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)
July 29, 2025
 · 
5 min read
Press Releases
Newleos Therapeutics Appoints Stephen Brannan to Board of Directors and Announces NTX-1955 Clinical Progress in Generalized Anxiety Disorder
July 23, 2025
 · 
6 min read
Press Releases
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
July 10, 2025
 · 
7 min read
Press Releases
Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo
July 9, 2025
 · 
13 min read
Press Releases
MapLight Therapeutics Announces Initiation of Phase 2 Trial of Its Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Schizophrenia
July 8, 2025
 · 
3 min read
Press Releases
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
July 2, 2025
 · 
11 min read
Press Releases
Avata Biosciences Signs Co-Development and Licensing Agreement with Oceanus Bio for Exclusive Rights in Japan and Asia (Excluding China and India) for Novel Adult and Pediatric Oral Cannabidiol Therapies for Development in Epilepsy and Schizophrenia
June 17, 2025
 · 
3 min read
Press Releases
diaMentis selected by Dassault Systèmes to join an exclusive group of innovative companies in the 3DEXPERIENCE Lab accelerator program
June 13, 2025
 · 
2 min read
Press Releases
Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
June 2, 2025
 · 
10 min read
Press Releases
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
June 2, 2025
 · 
22 min read
Load More